Denali Therapeutics Inc. Files Definitive Proxy Statement

TL;DR

<b>Denali Therapeutics Inc. has filed its Definitive Proxy Statement for the fiscal year ending December 31, 2023.</b>

AI Summary

Denali Therapeutics Inc. (DNLI) filed a Proxy Statement (DEF 14A) with the SEC on April 18, 2024. Denali Therapeutics Inc. filed a Definitive Proxy Statement (DEF 14A) on April 18, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 161 Oyster Point Blvd., South San Francisco, CA 94080. The filing includes information related to equity award adjustments for the fiscal years 2020 through 2023. Denali Therapeutics Inc. is classified under SIC code 2836 for Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking Denali Therapeutics Inc., this filing contains several important signals. This DEF 14A filing provides shareholders with crucial information regarding executive compensation, board nominations, and other corporate governance matters, enabling informed voting decisions. The detailed breakdown of equity award adjustments over multiple fiscal years offers insight into the company's long-term incentive strategies and potential dilution effects for shareholders.

Risk Assessment

Risk Level: low — Denali Therapeutics Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for publicly traded companies and does not contain new material financial or operational information.

Analyst Insight

Review the executive compensation details and any proposed changes to governance policies to understand potential impacts on shareholder value and company direction.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-04-18 — Filing Date (Filed as of Date)
• 2836 — SIC Code (Standard Industrial Classification)

Key Players & Entities

• Denali Therapeutics Inc. (company) — Filer
• 161 Oyster Point Blvd. (location) — Business Address
• South San Francisco (location) — Business Address City
• CA (location) — Business Address State
• 94080 (location) — Business Address Zip

FAQ

Industry Context

Denali Therapeutics Inc. operates in the biotechnology sector, focusing on the development of therapies for neurodegenerative diseases.

Regulatory Implications

As a publicly traded company, Denali Therapeutics Inc. is subject to SEC regulations, including the requirement to file proxy statements detailing corporate governance and executive compensation.

What Investors Should Do

1. Analyze the detailed breakdown of equity awards granted and their fair value adjustments for the past four fiscal years.
2. Review the list of nominees for the board of directors and any proposed amendments to company bylaws or governance policies.
3. Examine the executive compensation disclosures, including base salary, bonuses, and stock awards, for key management personnel.

Key Dates

• 2024-04-18: Filing Date — Definitive Proxy Statement filed
• 2023-12-31: Fiscal Year End — Period covered by the filing

Year-Over-Year Comparison

This filing is a DEF 14A, which is a routine disclosure. No specific comparative data from a prior filing was immediately available in the provided text.

Filing Documents

• dnli-20240418.htm (DEF 14A) — 1076KB
• dnli-20240418_g1.jpg (GRAPHIC) — 26KB
• dnli-20240418_g10.jpg (GRAPHIC) — 200KB
• dnli-20240418_g2.jpg (GRAPHIC) — 12KB
• dnli-20240418_g3.jpg (GRAPHIC) — 16KB
• dnli-20240418_g4.jpg (GRAPHIC) — 15KB
• dnli-20240418_g5.jpg (GRAPHIC) — 20KB
• dnli-20240418_g6.jpg (GRAPHIC) — 44KB
• dnli-20240418_g7.jpg (GRAPHIC) — 118KB
• dnli-20240418_g8.jpg (GRAPHIC) — 106KB
• dnli-20240418_g9.jpg (GRAPHIC) — 462KB
• 0001714899-24-000110.txt (&nbsp;) — 4110KB
• dnli-20240418.xsd (EX-101.SCH) — 4KB
• dnli-20240418_def.xml (EX-101.DEF) — 2KB
• dnli-20240418_lab.xml (EX-101.LAB) — 8KB
• dnli-20240418_pre.xml (EX-101.PRE) — 5KB
• dnli-20240418_htm.xml (XML) — 149KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 32 DIRECTOR COMPENSATION 56 EQUITY COMPENSATION PLAN INFORMATION 59

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 60 RELATED PERSON TRANSACTIONS 63 OTHER MATTERS 65 DELINQUENT SECTION 16(A) REPORTS 66 PROPOSALS OF STOCKHOLDERS FOR 2024 ANNUAL MEETING 67 ADMISSION TICKET AND VOTING INSTRUCTIONS 68 -i- Table of Contents DENALI THERAPEUTICS INC. PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 10:00 a.m. Pacific Time on May 31, 2024 This proxy statement and form of proxy are furnished in connection with the solicitation of proxies by our board of directors (the "Board") for use at our 2024 Annual Meeting of Stockholders (the "Annual Meeting"), and any postponements, adjournments, or continuations thereof. Stockholders will not be able to physically attend the Annual Meeting. The Annual Meeting will be held virtually via live webcast on May 31, 2024 at 10:00 a.m. Pacific Time. You will be able to attend the virtual Annual Meeting by accessing www.virtualshareholdermeeting.com/DNLI2024 and entering the 16-digit control number found on your Notice of Internet Availability, your proxy card or on the instructions that accompany your proxy materials. The virtual format of the Annual Meeting allows us to preserve stockholder access while also saving time and money for both us and our stockholders. The Notice of Internet Availability of Proxy Materials (the "Notice") containing instructions on how to access this proxy statement and our annual report is first being mailed on or about April 18, 2024 to all stockholders entitled to vote at the virtual Annual Meeting. If you receive a Notice by mail, you will not receive a printed copy of the proxy materials in the mail unless you specifically request these materials. QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING The information provided in the "question and answer" format below addresses certain frequently asked questions but is not intended to be a summary of all matters contained in this proxy statement. Please read the entire

View Full Filing

View this DEF 14A filing on SEC EDGAR